RecruitingNot applicableNCT05053230
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Studying Gonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Karolina Bryl, PhDMemorial Sloan Kettering Cancer Center
- Intervention
- IM@Home(behavioral)
- Enrollment
- 480 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (7)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05053230 on ClinicalTrials.govOther trials for Gonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07318051Sample Collection for Ongoing Research and Product Evaluation StudyNatera, Inc.
- RECRUITINGNCT05645510LIVInG With chrONic Cancer TrEatments (LONGEVITI) StudyUniversity of Alberta
- RECRUITINGNANCT05142982Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced SeminomaTata Memorial Centre
- RECRUITINGPHASE1, PHASE2NCT04752826BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)BioInvent International AB
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04205227ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsENB Therapeutics, Inc
- ACTIVE NOT RECRUITINGPHASE1NCT03872947A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsToray Industries, Inc
- RECRUITINGNANCT03787056Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsHospices Civils de Lyon
- ACTIVE NOT RECRUITINGNANCT03418844Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of ChemotherapyCentre Francois Baclesse